Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

摘要: BackgroundDiabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 inhibitor, reduced major events in patients with type diabetes at high for We wanted to determine long-term effects analysis that was prespecified component secondary microvascular outcome trial. MethodsWe randomly assigned estimated glomerular filtration rate least 30 ml per minute 1.73 m2 body-surface area receive either empagliflozin (at dose 10 mg or 25 mg) placebo once daily. Prespecified outcomes included incident worsening nephropathy (progression macroalbuminuria, doubling serum creatinine level, initiation renal-replacement therapy, death from disease) albuminuria. ResultsIncident occurred ...